Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, KYNTRA BIO, INC. reported revenue of $6M, down 78.3% year over year. Operating margin was -712.7% and net margin 2848.6%, on a free-cash-flow margin of -74.7% with capital expenditure at 0.6% of revenue. Every figure is computed directly from KYNB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $6M | -712.7% | 2848.6% |
| FY2024 | $30M | -507.8% | -160.6% |
| FY2023 | $47M | -689.5% | -607.3% |
| FY2022 | $141M | -213.9% | -208.7% |
| FY2021 | $235M | -122.6% | -123.3% |
How does KYNB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.